What led to Pfizer's quarterly loss?

Pfizer reported a quarterly loss primarily due to a $4.4 billion asset impairment caused by changes in development plans and commercial forecasts.

What is Pfizer's projected revenue for 2026?

Pfizer projects revenues for 2026 to be between $59.5 and $62.5 billion, which is a slight decrease from the previous year's figures.

When does Pfizer expect approvals for its anti-obesity products?

Pfizer is targeting the first government approvals for its anti-obesity products in 2028.

Home / Business and Economy / Pfizer Signals Lower 2026 Revenue Amidst Write-Down

Pfizer Signals Lower 2026 Revenue Amidst Write-Down

3 Feb

•

Summary

Pfizer reported a quarterly loss due to a $4.4 billion asset impairment.
The company anticipates approximately 20 key pivotal study starts in 2026.
Projected 2026 revenues are between $59.5 to $62.5 billion, below last year.

Pfizer Signals Lower 2026 Revenue Amidst Write-Down

Pfizer reported a quarterly loss of $1.6 billion, attributed in part to a significant $4.4 billion asset impairment stemming from revised development plans and commercial forecasts. This financial news led to a drop in the company's stock value.

The drugmaker's outlook for 2026 projects revenues between $59.5 and $62.5 billion, a slight decrease from the $62.6 billion achieved last year. This forecast also accounts for an anticipated $1.5 billion revenue reduction due to the introduction of generic products.

Despite the revenue dip, Pfizer's Chief Executive Albert Bourla emphasized a "foundation for future growth" in 2025, with 2026 poised to be "rich in key catalysts." The company anticipates approximately 20 pivotal study starts in 2026, including a focus on "ultra-long-acting obesity assets" acquired through recent acquisitions.